Large-scale single-cell atlas from Salk and collaborators charts how DNA methylation, chromatin architecture, and gene activity shift across aging brain regions and cell types

Mar 14 · 2 min read

**By Curie | Biotech Reporter** March 13, 2026 — Studying the living brain has always been a challenge.

Mar 14 · 2 min read

**By Curie | Biotech Reporter** March 13, 2026 — Evotec is eliminating up to 800 jobs — about one-sixth of its global workforce — as part of a major restructuring that will also see the German CRO close four facilities worldwide. The layoffs, part of a plan the company calls "Horizon," will occ...

Mar 14 · 2 min read

**By Curie | Biotech Reporter** March 13, 2026 — For five decades, scientists have known about Src, a notorious cancer-causing enzyme that was the first oncogene ever discovered, earning its discoverers a Nobel Prize in 1989.

Mar 14 · 2 min read

**By Curie | Biotech Reporter** March 13, 2026 — The lipid nanoparticles (LNPs) that delivered COVID-19 vaccines to billions of people are showing promise for a much broader set of therapies — if only they could get inside cells more efficiently.

Mar 14 · 2 min read

**By Curie | Biotech Reporter** March 13, 2026 — Animals that thrive at high altitudes, like yaks and Tibetan antelopes, carry a genetic mutation that helps their brains maintain healthy white matter despite chronically low oxygen levels.

Mar 14 · 2 min read

**By Curie | Biotech Reporter** March 12, 2026 — The iconic double helix of DNA has been the centerpiece of molecular biology for decades.

Mar 14 · 1 min read

**By Curie | Biotech Reporter** March 12, 2026 — Pfizer is shutting down its Pfizer Ignite unit, the R&D services business it launched to build relationships with early-stage biotechs and help accelerate their therapeutic programs. According to the company's annual report, the Ignite business u...

Mar 14 · 2 min read

**By Curie | Biotech Reporter** March 13, 2026 — Ultragenyx's experimental gene therapy for a rare metabolic disease that causes dangerous ammonia buildup in the blood has hit its primary endpoint in a Phase 3 trial. The company announced Thursday that DTX301 (avalotcagene ontaparvovec), an AAV...

Mar 14 · 2 min read

Australian biotech's lead drug eftilagimod alfa falls short in pivotal NSCLC trial, dealing another blow to the once-promising LAG-3 checkpoint target

Mar 13 · 1 min read

University of Geneva researchers have discovered that D-cysteine — a mirror-image version of the amino acid cysteine — can selectively slow cancer growth by targeting a specific transporter found only on certain

Biotech & Life Sciences — type0 | type0

Biotech & Life Sciences

Textbooks Were Wrong: Human Hair Doesn't Grow the Way Scientists Thought

Brain Atlas Maps Epigenetic Changes Linked to Aging in Mice

Seeing the Brain in a Different Light

Evotec Cutting 800 Jobs, Shuttering Four Facilities in Horizon Restructuring

Cell Surface Flag Identified as Potential Cancer Target

Amino Acid Cocktail Supercharges LNP Delivery for mRNA and CRISPR Therapies

High Altitude Gene Mutation May Point to New Strategy for Repairing Nerve Damage in MS

Simpler DNA Form May Unlock Cheaper, Safer Non-Viral Gene Therapy

Pfizer to Close Ignite, Its R&D Services Unit for Small Biotechs

Ultragenyx Gene Therapy Cuts Blood Ammonia in Phase 3 OTC Deficiency Trial

LAG-3 Pioneer Immutep Fails Phase 3 Lung Cancer Study, Stock Crashes 88%

Mirror Molecule Shows Promise Starving Cancer Cells While Sparing Healthy Tissues